Anti-Coagulants - G7

The Anti-Coagulants market in the G7 countries is expected to witness substantial growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$22.22bn by 2024.
Furthermore, it is anticipated that the market will exhibit a compound annual growth rate (CAGR) of 6.01% between 2024 and 2029, resulting in a market volume of US$29.75bn by the end of 2029.
When comparing the revenue generated in the Anti-Coagulants market globally, it is evident that United States will hold the leading position.
In 2024 alone, United States is expected to generate a revenue of US$16,740.00m.
This highlights the significant contribution of the United States to the overall market performance in the G7 countries.
In the United States, the growing demand for novel oral anticoagulants is driving the shift away from traditional warfarin therapy.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in G7 has been experiencing significant growth in recent years, driven by several factors.

Customer preferences: One of the primary drivers of growth in the Anti-Coagulants market in G7 is the increasing prevalence of cardiovascular diseases and strokes. As a result, there is a growing demand for drugs that can prevent blood clots and reduce the risk of these conditions. Additionally, an aging population and changing lifestyles have contributed to the rise in demand for Anti-Coagulants.

Trends in the market: In the United States, the Anti-Coagulants market has been dominated by newer oral anticoagulants, which have gained popularity due to their ease of use and lower risk of bleeding. However, the market for traditional anticoagulants such as warfarin remains significant, particularly in older patients and those with certain medical conditions. In Europe, newer oral anticoagulants have also gained popularity, but warfarin remains the most commonly prescribed anticoagulant in many countries. In Japan, the Anti-Coagulants market is dominated by warfarin due to regulatory restrictions on newer drugs.

Local special circumstances: In France, the Anti-Coagulants market is heavily regulated, with strict controls on pricing and reimbursement. This has led to a slower uptake of newer oral anticoagulants compared to other G7 countries. In Germany, the market is highly competitive, with several domestic and international players vying for market share. This has led to aggressive pricing strategies and the introduction of innovative drugs to gain a competitive edge. In the UK, the National Health Service (NHS) is a major player in the Anti-Coagulants market, and decisions made by the NHS regarding drug reimbursement can have a significant impact on the market.

Underlying macroeconomic factors: The Anti-Coagulants market in G7 is also influenced by broader macroeconomic factors such as healthcare expenditure and regulatory policies. Rising healthcare expenditure in many G7 countries has led to increased funding for research and development of new drugs, as well as greater access to healthcare services for patients. Regulatory policies regarding drug pricing and reimbursement can also impact the market, particularly in countries such as France where pricing is heavily regulated. Additionally, the impact of Brexit on the pharmaceutical industry and drug regulation in the UK remains uncertain and could have significant implications for the Anti-Coagulants market in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.